
Dec 31 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS PROVIDES REGULATORY UPDATE ON U.S. FOOD AND DRUG ADMINISTRATION REVIEW OF ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) FOR THE TREATMENT OF WET AMD
OUTLOOK THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR ONS-5010 BLA
OUTLOOK THERAPEUTICS INC: CURRENTLY EXPLORING ALL AVAILABLE PATHWAYS FOR POTENTIAL APPROVAL IN U.S
OUTLOOK THERAPEUTICS INC - FDA RECOMMENDS CONFIRMATORY EVIDENCE FOR ONS-5010 APPROVAL
OUTLOOK THERAPEUTICS INC: FDA HAS NOT INDICATED WHAT TYPE OF CONFIRMATORY EVIDENCE WOULD BE ACCEPTABLE